Summit Therapeutics
SMMT
17.95
+0.64
+3.70%
Summit Therapeutics
US · SMMT
#1207 by market cap
Listed 2015
17.95
+0.64
+3.70%
Live - 5344 symbols - heartbeat 56s ago
· 2026-10-08 06:49
Pre-market
17.80
-0.84%
After-hours
17.97
+0.11%
Overnight
17.71
-1.34%
- Market cap
- 14.32B
- P/E (TTM)i
- -16.17
- P/Bi
- 22.72
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on SMMT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 15 analysts
Buy
Avg price target
29.58 +64.8%
Price target rangecurrent 17.95
Low9.80
Avg29.58
High43.00
Buy 67%
Hold 27%
Sell 7%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Barclays | -- | HOLD | 20.00 |
| 2026-09-30 | Citi | -- | BUY | 43.00 |
| 2026-09-30 | H.C. Wainwright | -- | HOLD | -- |
| 2026-09-29 | Piper Sandler | -- | HOLD | 16.00 |
| 2026-09-29 | Jefferies | -- | BUY | -- |
| 2026-09-29 | Evercore | -- | BUY | 34.00 |
| 2026-09-29 | Stifel | -- | BUY | -- |
| 2026-09-29 | Citi | -- | BUY | 43.00 |
| 2026-09-29 | H.C. Wainwright | -- | HOLD | -- |
| 2026-09-28 | Wells Fargo | -- | BUY | 30.00 |
| 2026-09-28 | UBS | -- | BUY | 33.00 |
| 2026-09-23 | H.C. Wainwright | -- | HOLD | -- |
| 2026-09-21 | Barclays | -- | HOLD | 18.00 |
| 2026-09-13 | UBS | -- | BUY | 33.00 |
| 2026-09-13 | Citi | -- | BUY | 40.00 |
| 2026-09-13 | Goldman Sachs | -- | BUY | 41.00 |
| 2026-09-09 | Jefferies | -- | BUY | 25.00 |
| 2026-09-08 | UBS | -- | BUY | 33.00 |
| 2026-09-03 | Clear Street | -- | BUY | 31.00 |
| 2026-09-03 | H.C. Wainwright | -- | HOLD | -- |
| 2026-09-02 | Citi | -- | BUY | 40.00 |
| 2026-09-02 | Goldman Sachs | -- | BUY | 41.00 |
| 2026-08-26 | Wells Fargo | -- | BUY | 30.00 |
| 2026-08-26 | H.C. Wainwright | -- | HOLD | -- |
| 2026-08-25 | Citi | -- | BUY | 40.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 1
■ Upgrades■ Downgrades
- 2 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Jefferies moved from Hold to Buy on 2026-09-09.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-09 | Jefferies | HOLD → BUY | 25.00 |
| 2026-05-22 | H.C. Wainwright | BUY → HOLD | -- |
| 2025-12-17 | Barclays | SELL → HOLD | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-23 | After close | ±16.02% | -8.81% (in line) |
| 2025/Q4 | 2026-02-23 | After close | ±9.35% | +0.19% (in line) |
| 2025/Q3 | 2025-10-20 | -- | ±21.61% | -4.55% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±12.42% | +13.09% (beat) |
| 2024/Q4 | 2025-02-24 | -- | ±14.52% | -14.83% (beat) |
| 2024/Q3 | 2024-10-30 | -- | ±9.81% | -14.57% (beat) |
| 2024/Q2 | 2024-08-06 | -- | ±15.76% | -4.74% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±26.01% | +19.59% (in line) |
| 2023/Q4 | 2024-02-20 | -- | ±22.19% | -26.23% (beat) |
| 2023/Q3 | 2023-11-07 | -- | ±31.74% | -12.16% (in line) |
| 2023/Q2 | 2023-08-09 | -- | ±19.66% | +10.86% (in line) |
| 2023/Q1 | 2023-05-11 | -- | ±12.03% | -9.20% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:49:11 · For reference only, not investment advice and not tailored to your situation.